Franz-Werner Haas | CEO |
Pierre Kemula | CFO |
Ulrike Gnad-Vogt | Interim Chief Development Officer |
Ronald Plasterk | SVP Science & Innovation |
Sarah Fakih | VP Corporate Communications and IR |
Geoff Meacham | Bank of America |
Evan Wang | Guggenheim |
Jonathan Miller | Evercore |
Roy Buchanan | JMP Securities |
Zhiqiang Shu | Berenberg |
Greetings, and welcome to CureVac Third Quarter and First Nine Months 2022 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions].
As a reminder, this conference is being recorded.